
    the study was terminated based on the results of a planned interim analysis that showed
    futility of efficacy.
  
['ovarian cancer']
['carboplatin', 'paclitaxel', 'avelumab', 'avelumab']

        Key Inclusion Criteria:

          -  Histologically confirmed Stage III-IV epithelial ovarian, fallopian tube, or primary
             peritoneal cancer, including malignant mixed Müllerian tumors with high grade serous
             component

          -  Patients must be candidates for platinum based chemotherapy and previously untreated

          -  Patients must have completed a surgical debulking procedure, or be candidates for
             neoadjuvant chemotherapy

          -  Availability of an archival formalin fixed, paraffin embedded (FFPE) tumor tissue
             block or a minimum of 15 slides

          -  ECOG PS 0-1

          -  Adequate hematological, renal, and liver function

        Key Exclusion Criteria:

          -  Non epithelial tumors or ovarian tumors with low malignant potential (ie, borderline
             tumors) or mucinous tumors

          -  Prior systemic anti-cancer treatment for EOC, FTC, or PPC including prior
             immunotherapy with IL 2, IFN α, or anti PD 1, anti PD L1, anti PD L2, anti CD137, or
             anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody (including
             ipilimumab), or any other antibody or drug specifically targeting T cell co
             stimulation or immune checkpoint pathways

          -  Patients for whom, in the opinion of the Investigator, there is clinical benefit to
             administer bevacizumab as a first-line treatment and for whom bevacizumab is approved
             and available in this setting.

          -  Cancer for which intraperitoneal cytotoxic chemotherapy is planned

          -  Active autoimmune disease (some exceptions include diabetes type I, vitiligo,
             psoriasis, hypo- or hyperthyroidism not requiring immunosuppressive treatment)
      